- Home
- HYPR vs VNRX Comparison
HYPR vs VNRX Comparison
Compare HYPR & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- VNRX
- Stock Information
- Founded
- HYPR 2014
- VNRX N/A
- Country
- HYPR United States
- VNRX United States
- Employees
- HYPR N/A
- VNRX N/A
- Industry
- HYPR Medical Specialities
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HYPR Health Care
- VNRX Health Care
- Exchange
- HYPR Nasdaq
- VNRX Nasdaq
- Market Cap
- HYPR 55.9M
- VNRX 52.4M
- IPO Year
- HYPR N/A
- VNRX N/A
- Fundamental
- Price
- HYPR $1.08
- VNRX $0.75
- Analyst Decision
- HYPR Strong Buy
- VNRX Strong Buy
- Analyst Count
- HYPR 3
- VNRX 5
- Target Price
- HYPR $1.06
- VNRX $3.88
- AVG Volume (30 Days)
- HYPR 459.6K
- VNRX 156.5K
- Earning Date
- HYPR 08-07-2025
- VNRX 08-13-2025
- Dividend Yield
- HYPR N/A
- VNRX N/A
- EPS Growth
- HYPR N/A
- VNRX N/A
- EPS
- HYPR N/A
- VNRX N/A
- Revenue
- HYPR $11,732,000.00
- VNRX $1,308,361.00
- Revenue This Year
- HYPR $12.31
- VNRX $563.72
- Revenue Next Year
- HYPR $29.29
- VNRX $160.43
- P/E Ratio
- HYPR N/A
- VNRX N/A
- Revenue Growth
- HYPR 0.34
- VNRX 64.16
- 52 Week Low
- HYPR $0.53
- VNRX $0.40
- 52 Week High
- HYPR $1.90
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- HYPR 66.05
- VNRX 55.55
- Support Level
- HYPR $0.91
- VNRX $0.71
- Resistance Level
- HYPR $1.20
- VNRX $0.79
- Average True Range (ATR)
- HYPR 0.09
- VNRX 0.06
- MACD
- HYPR 0.03
- VNRX -0.00
- Stochastic Oscillator
- HYPR 72.73
- VNRX 71.43
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.